Pheneturide

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Pheneturide
Pheneturide.svg
Clinical data
AHFS/Drugs.com International Drug Names
ATC code
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ECHA InfoCard 100.001.817
Chemical and physical data
Formula C11H14N2O2
Molar mass 206.241 g/mol
3D model (JSmol)
Chirality Racemic mixture
 NYesY (what is this?)  (verify)

Pheneturide (INN, BAN) (brand names Benuride, Deturid, Pheneturid, Septotence, Trinuride),[1] also known as phenylethylacetylurea (or ethylphenacemide), is an anticonvulsant of the ureide class.[2][3] Conceptually, it can be formed in the body as a metabolic degradation product from [[phenobarbital]]. It is considered to be obsolete,[4] and is now seldom used.[5] It is marketed in Europe, including in Poland, Spain, and the United Kingdom.[6] Pheneturide has a similar profile of anticonvulsant activity and toxicity relative to phenacemide,[7] but is less toxic in comparison, despite still being a toxic drug.[8] As such, it is only used in cases of severe epilepsy when other, less-toxic drugs have failed.[8] Pheneturide inhibits the metabolism and thus increases the levels of other anticonvulsants, such as phenytoin.[5][6]

See also[edit]

References[edit]

  1. ^ Muller (19 June 1998). European Drug Index: European Drug Registrations, Fourth Edition. CRC Press. pp. 998–. ISBN 978-3-7692-2114-5. 
  2. ^ J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 959–. ISBN 978-1-4757-2085-3. 
  3. ^ Byrne B, Rothchild R (1999). "1H NMR studies of drugs with achiral and chiral lanthanide shift reagents: applications to the anticonvulsant pheneturide". Chirality. 11 (7): 529–35. PMID 10423278. doi:10.1002/(SICI)1520-636X(1999)11:7<529::AID-CHIR3>3.0.CO;2-K. 
  4. ^ René H. Levy (2002). Antiepileptic Drugs. Lippincott Williams & Wilkins. pp. 210–. ISBN 978-0-7817-2321-3. 
  5. ^ a b M.J. Denham (6 December 2012). The Treatment of Medical Problems in the Elderly. Springer Science & Business Media. pp. 335–. ISBN 978-94-011-6223-4. 
  6. ^ a b Julius Vida (19 July 2013). Anticonvulsants. Elsevier. pp. 4,42. ISBN 978-0-323-14395-0. 
  7. ^ deStevens, G.; Zingel, V.; Leschke, C.; Hoeprich, P.D.; Schultz, R.M.; Mehrotra, P.K.; Batra, S.; Bhaduri, A.P.; Saxena, A.K.; Saxena, M., eds. (11 November 2013). Progress in Drug Research / Fortschritte der Arzneimittelforschung / Progrès des Recherches Pharmaceutiques. Basel: Birkhäuser. pp. 217–. ISBN 978-3-0348-7161-7. Retrieved 3 September 2016. 
  8. ^ a b Richard Lancaster (22 October 2013). Pharmacology in Clinical Practice. Elsevier. pp. 222–. ISBN 978-1-4831-9294-9.